Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

曲妥珠单抗 医学 内科学 中期分析 肿瘤科 乳腺癌 临床终点 人口 佐剂 外科 临床试验 危险系数 癌症 置信区间 环境卫生
作者
Luca Gianni,Urania G. Dafni,Richard D. Gelber,Evandro de Azambuja,Susanne Muehlbauer,Aron Goldhirsch,Michael Untch,Ian Smith,Jose M Baselga,Christian Jackisch,David Cameron,Max S. Mano,José Luiz Pedrini,Andrea Veronesi,César Mendiola,Anna Pluzanska,Владимир Федорович Семиглазов,Eduard Vrdoljak,Michael Josef Eckart,Zhenzhou Shen
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:12 (3): 236-244 被引量:607
标识
DOI:10.1016/s1470-2045(11)70033-x
摘要

Background Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial. Methods The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant, adjuvant chemotherapy, or both in patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. After a positive first interim analysis at a median follow-up of 1 year for the comparison of treatment with trastuzumab for 1 year with observation, event-free patients in the observation group were allowed to cross over to receive trastuzumab. We report trial outcomes for the 1-year trastuzumab and observation groups at a median follow-up of 48·4 months (IQR 42·0–56·5) and assess the effect of the extensive crossover to trastuzumab. Our analysis was by intention-to-treat. The HERA trial is registered with the European Clinical Trials Database, number 2005-002385-11. Findings The HERA trial population comprised 1698 patients randomly assigned to the observation group and 1703 to the 1-year trastuzumab group. Intention-to-treat analysis of disease-free survival showed a significant benefit in favour of patients in the 1-year trastuzumab group (4-year disease-free survival 78·6%) compared with the observation group (4-year disease-free survival 72·2%; hazard ratio [HR] 0·76; 95% CI 0·66–0·87; p<0·0001). Intention-to-treat analysis of overall survival showed no significant difference in the risk of death (4-year overall survival 89·3% vs 87·7%, respectively; HR 0·85; 95% CI 0·70–1·04; p=0·11). Overall, 885 patients (52%) of the 1698 patients in the observation group crossed over to receive trastuzumab, and began treatment at median 22·8 months (range 4·5–52·7) from randomisation. In a non-randomised comparison, patients in the selective-crossover cohort had fewer disease-free survival events than patients remaining in the observation group (adjusted HR 0·68; 95% CI 0·51–0·90; p=0·0077). Higher incidences of grade 3–4 and fatal adverse events were noted on 1-year trastuzumab than in the observation group. The most common grade 3 or 4 adverse events, each in less than 1% of patients, were congestive cardiac failure, hypertension, arthralgia, back pain, central-line infection, hot flush, headache, and diarrhoea. Interpretation Treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4-year median follow-up. The substantial selective crossover of patients in the observation group to trastuzumab was associated with improved outcomes for this cohort. Funding F Hoffmann-La Roche, Michelangelo Foundation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
qiqi发布了新的文献求助10
2秒前
2秒前
wanci的应助被小小怪采纳,获得10
2秒前
wangbw发布了新的文献求助10
2秒前
3秒前
Pupupapa完成签到,获得积分20
3秒前
lulu完成签到,获得积分10
4秒前
Bai发布了新的文献求助10
4秒前
Akim的应助被blinkals57采纳,获得10
4秒前
ui24发布了新的文献求助10
4秒前
4秒前
淡定访琴完成签到,获得积分10
5秒前
搜集达人的应助被mhx1234567890采纳,获得10
6秒前
8秒前
孤独的凤完成签到,获得积分10
8秒前
9秒前
9秒前
音阙发布了新的文献求助10
9秒前
Sxya发布了新的文献求助30
10秒前
dingyushu完成签到,获得积分10
10秒前
秋风的应助被pinkstar采纳,获得10
10秒前
科研通AI6.3的应助被向星采纳,获得10
11秒前
11秒前
11秒前
dkfsgeicn完成签到,获得积分10
12秒前
情怀的应助被ZYH采纳,获得10
12秒前
13秒前
orixero的应助被Kevin采纳,获得10
13秒前
phoebe发布了新的文献求助10
14秒前
研友_VZG7GZ的应助被香辣牛排采纳,获得10
14秒前
14秒前
15秒前
2dingyushu完成签到,获得积分10
15秒前
852的应助被甜蜜的电灯胆采纳,获得10
15秒前
科研通AI6.3的应助被晚风采纳,获得10
15秒前
melon发布了新的文献求助20
15秒前
疯狂加载ing的应助被hin采纳,获得10
16秒前
wangbw发布了新的文献求助10
17秒前
缺口口发布了新的文献求助80
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593